1. Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue decline; 2. Recent acquisitions and product launches in oncology and vaccines strengthen Pfizer's market position and future revenue streams; 3. Despite potential risks like tariffs and drug development delays, Pfizer's current valuation is attractive, resembling 2008-2009 levels.